- Home
- NCV vs CLLS Comparison
NCV vs CLLS Comparison
Compare NCV & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCV
- CLLS
- Stock Information
- Founded
- NCV 2003
- CLLS 1999
- Country
- NCV United States
- CLLS France
- Employees
- NCV N/A
- CLLS N/A
- Industry
- NCV Finance Companies
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NCV Finance
- CLLS Health Care
- Exchange
- NCV Nasdaq
- CLLS Nasdaq
- Market Cap
- NCV 326.0M
- CLLS 299.0M
- IPO Year
- NCV N/A
- CLLS 2007
- Fundamental
- Price
- NCV $15.11
- CLLS $2.99
- Analyst Decision
- NCV
- CLLS Buy
- Analyst Count
- NCV 0
- CLLS 1
- Target Price
- NCV N/A
- CLLS $4.00
- AVG Volume (30 Days)
- NCV 405.1K
- CLLS 77.9K
- Earning Date
- NCV 01-01-0001
- CLLS 11-03-2025
- Dividend Yield
- NCV 12.48%
- CLLS N/A
- EPS Growth
- NCV N/A
- CLLS N/A
- EPS
- NCV N/A
- CLLS N/A
- Revenue
- NCV N/A
- CLLS $63,438,000.00
- Revenue This Year
- NCV N/A
- CLLS N/A
- Revenue Next Year
- NCV N/A
- CLLS $66.76
- P/E Ratio
- NCV N/A
- CLLS N/A
- Revenue Growth
- NCV N/A
- CLLS 223.09
- 52 Week Low
- NCV $2.84
- CLLS $1.10
- 52 Week High
- NCV $3.59
- CLLS $3.35
- Technical
- Relative Strength Index (RSI)
- NCV 66.45
- CLLS 61.44
- Support Level
- NCV $14.65
- CLLS $2.88
- Resistance Level
- NCV $15.29
- CLLS $3.35
- Average True Range (ATR)
- NCV 0.14
- CLLS 0.17
- MACD
- NCV 0.03
- CLLS 0.01
- Stochastic Oscillator
- NCV 75.66
- CLLS 57.65
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.